Analyze the Cardiovascular Benefits of the Different GLP-1 Agonists

Dulaglutide (Trulicity) will be the third GLP-1 agonist to show CV benefits in some patients with type 2 diabetes.

It joins semaglutide (Ozempic) and liraglutide (Victoza). All three lower CV risk in type 2 patients with CV disease or at high CV risk.

Each of these meds also seems to slow progression to albuminuria...but none have been shown to delay dialysis.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals